Medical Communication Consultants and Artificial Intelligence Company ClinGenuity Merge

Medical Communication Consultants, a Cincinnati medical writing company, and ClinGenuity, the first artificially-intelligent tool in the pharmaceutical industry, will merge to increase development efficiencies and help reduce new drug and medical device development cycle times and costs.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
“This merger is significant on various levels and emphasizes the move toward technology-enabled service solutions the pharmaceutical industry not only desires, but desperately needs,” said Kleeman.

CINCINNNATI, Ohio (PRWEB) May 21, 2014

Medical Communication Consultants, LLC (MCC) and ClinGenuity, LLC today announced they have merged to create the only technology-enabled medical writing solution in the pharmaceutical industry.

The merger combines MCC, one of the largest and most well-respected manual medical writing companies with ClinGenuity, the first artificially-intelligent tool in the pharmaceutical industry, creating an unparalleled technology-enabled medical writing offering for global pharmaceutical clients, said Keith Kleeman, chief executive officer who co-founded both companies.

Kleeman announced the merger today. The new company will operate under the ClinGenuity name moving forward.

“We are excited to be the only company in the CRO industry to offer a technology-enabled medical writing service that includes full service authoring for both regulatory and commercial projects” said Kleeman. “Our combined offering will meet customer needs beyond anything else offered in the industry and we believe will be the new standard for medical writing moving forward.”

MCC ‘s staff of expert medical writers is one of the largest and most veteran in the industry. It integrates a pharmaceutical client’s systems and requirements and scales them to meet project needs with its Writer Initiative Network (WIN).

It differs from most other medical writing vendors, who assign their writers to projects based on availability. MCC’s WIN allows it to expertly match writers to each project by experience and area of medical writing expertise.

ClinGenuity, the pharmaceutical industry’s first AI tool, automates the generation of numerous clinical documents, significantly reducing cycle times and drug development costs.

For example, ClinGenuity’s Report Writer tool generates 90-percent complete, fully-compliant clinical study reports (CSRs) in less than an hour, freeing up medical writers and clinical study teams to do what they do best—interpreting data and driving new development.

“When I founded MCC and created the industry’s first Writers Initiative Network (WIN), the process of creating a clinical study report and other regulatory documents was speeded considerably by matching expertise with project need,” said Kleeman. “But any fast human, even when perfectly matched by experience to project need, is slow compared to an AI tool. The ultimate goal has always been to offer the absolute best medical writing talent, aided by the most technologically advanced tools in the industry. The merger of MCC and ClinGenuity delivers on that objective.”

ClinGenuity and MCC have long proven to be independent, innovative companies, developing technologies and processes that not only push development into the future, but also produce tools and outcomes others in the industry believed to be impossible, said Kleeman.

The combination of the two companies furthers this development and innovation, and multiplies the benefits for pharma clients beyond what either company could provide alone, he added.

“This merger is significant on various levels and emphasizes the move toward technology-enabled service solutions the pharmaceutical industry not only desires, but desperately needs,” said Kleeman.

With ClinGenuity’s AI tool and WIN’s expert writers, Kleeman estimated ClinGenuity can save a pharmaceutical client about 20 weeks of protected revenue, or up to $500 million, that could otherwise be lost to generics.

“No one else has this technology, so no one else can market it,” said Kleeman. “We are rapidly gaining market share as a result, and expect to continue pushing our development and pipeline forward for our valued clients.”        

For more information on ClinGenuity, go to http://www.clingenuity.com or call (513) 239-6918.                                                    

#     #     #

Contact: Keith Kleeman
Email: kkleeman(at)clingenuity(dot)com
Phone: 513. 239-6918

About ClinGenuity:

ClinGenuity, a Cincinnati-based medical writing company using expert medical writers assigned to each project according to expertise and the only artificially-intelligent tool in the pharmaceutical industry, increases new drug and medical device development efficiencies to help reduce development cycle times and costs.


Contact

Attachments

MCC President MCC President

Keith Kleeman


Medical Communication Consultants